Medical Excellence Capital<\/a>, Heil met Schafmeister about a year and a half ago.<\/p>\n\u201cWe got to know each other around Chris\u2019s vision for this chemistry as medicines, not just for diagnostic applications,\u201d Heil said. \u201cAs an investor, I saw the potential in therapeutics as well.\u201d<\/p>\n
Medical Excellence Capital went on to lead Ladder Bio\u2019s seed financing. Heil then moved from backing the company to helping run it, joining as CEO to guide its push into drug development while the company builds out its leadership team.<\/p>\n
Ladder Bio has raised $6.55 million from investors to date, and currently has a 10-person team consisting mostly of chemists, along with a small biology group leading preclinical development.<\/p>\n
Schafmeister remains the inventor and scientific force behind the platform, while Heil is focused on turning it into a business that can bring drug candidates into clinical trials.<\/p>\n
Using software to find the right fit<\/p>\n
Ladder Bio uses its own AI software to help decide which molecules to build.<\/p>\n
\u201cChris has designed a software application called CanDo that can take that protein target and go through the building blocks to find the most optimal spot on that protein,\u201d Heil said. The software then identifies which combination of building blocks is needed for that target.<\/p>\n
Heil compared the process to software that designs a Lego model, then produces a list of the exact pieces needed to assemble it. Ladder Bio can snap together its chemical building blocks in different arrangements, much like Lego pieces, to produce molecules with different shapes and properties.<\/p>\n
CanDo helps researchers narrow down which molecules are most promising to make and test. The combination of software and modular chemistry, Schafmeister said, could make that search for what he calls \u201cGoldilocks molecules\u201d \u2014 which occupy a middle ground between conventional small-molecule drugs and much larger biologic medicines, such as antibodies \u2014 more precise.<\/p>\n
In addition to beginning its first human study within two years, Heil said the company plans to have several programs in clinical trials within five years and eventually develop medicines that can be prescribed to patients. The company is also in talks with pharmaceutical partners interested in applying its chemistry to their own drug programs, alongside plans to raise additional funding later this year.<\/p>\n
He envisions Ladder Bio as someday being a Philadelphia success story.<\/p>\n
During a recent visit to the Museum of the American Revolution, Heil walked past the former headquarters of Rohm and Haas, the Philadelphia chemical company that grew into a global business.<\/p>\n
\u201cI believe Ladder Bio could be the next Rohm and Haas, but for therapeutics and diagnostics using this chemistry set,\u201d Heil said. \u201cIt is an entirely new world of chemical structures that have infinite possibilities of applications.\u201d<\/p>\n
This story is made possible thanks to support from\u00a0Ben Franklin Technology Partners of Southeastern Pennsylvania<\/a>, a nonprofit that leads the Philadelphia region\u2019s equitable economic growth by nurturing and investing in innovative, early-stage companies, and through purposeful involvement in regional and national initiatives. All stories are independently reported, with no partner review.<\/p>\n","protected":false},"excerpt":{"rendered":"For medicine to work, it needs to be able to reach its target. For many drugs, that means…\n","protected":false},"author":2,"featured_media":222319,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[25706,33067,69,71,70,5399],"class_list":["post-222318","post","type-post","status-publish","format-standard","has-post-thumbnail","category-philadelphia","tag-biotechnology","tag-health-tech","tag-philadelphia","tag-philadelphia-headlines","tag-philadelphia-news","tag-startups"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts\/222318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/comments?post=222318"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts\/222318\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/media\/222319"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/media?parent=222318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/categories?post=222318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/tags?post=222318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}